https://wikem.org/w/index.php?action=history&feed=atom&title=Clinical_institute_withdrawal_assessment_for_benzodiazepines 2026-04-20T21:14:48Z Revision history for this page on the wiki MediaWiki 1.38.2 https://wikem.org/w/index.php?title=Clinical_institute_withdrawal_assessment_for_benzodiazepines&diff=388476&oldid=prev 2026-03-22T05:31:23Z

<p>Danbot moved page <a href="/wiki/Clinical_Institute_Withdrawal_Assessment_for_Benzodiazepines" class="mw-redirect" title="Clinical Institute Withdrawal Assessment for Benzodiazepines">Clinical Institute Withdrawal Assessment for Benzodiazepines</a> to <a href="/wiki/Clinical_institute_withdrawal_assessment_for_benzodiazepines" title="Clinical institute withdrawal assessment for benzodiazepines">Clinical institute withdrawal assessment for benzodiazepines</a> without leaving a redirect: Naming convention: first word capitalized, subsequent words lowercase</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <tr class="diff-title" lang="es"> <td colspan="1" style="background-color: #fff; color: #202122; text-align: center;">← Revisión anterior</td> <td colspan="1" style="background-color: #fff; color: #202122; text-align: center;">Revisión del 05:31 22 mar 2026</td> </tr><tr><td colspan="2" class="diff-notice" lang="es"><div class="mw-diff-empty">(Sin diferencias)</div> </td></tr></table>

Danbot https://wikem.org/w/index.php?title=Clinical_institute_withdrawal_assessment_for_benzodiazepines&diff=376426&oldid=prev 2025-05-05T15:58:05Z

<p>Created page with &quot;== Overview == The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) is a clinician-administered tool used to assess the severity of benzodiazepine withdrawal symptoms and guide treatment decisions. While less widely validated than its counterpart for alcohol (CIWA-Ar), CIWA-B offers a structured approach to monitor symptom progression and response to therapy. == Components == CIWA-B typically includes scoring across the following domains: * Anxiety...&quot;</p> <p><b>Página nueva</b></p><div>== Overview ==<br /> The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) is a clinician-administered tool used to assess the severity of benzodiazepine withdrawal symptoms and guide treatment decisions. While less widely validated than its counterpart for alcohol (CIWA-Ar), CIWA-B offers a structured approach to monitor symptom progression and response to therapy.<br /> <br /> == Components ==<br /> CIWA-B typically includes scoring across the following domains:<br /> <br /> * Anxiety<br /> * Sensory disturbances (e.g., hyperacusis, photophobia)<br /> * Headache or fullness in head<br /> * Tremor<br /> * Nausea/vomiting<br /> * Tension or restlessness<br /> * Depersonalization or derealization<br /> * Visual or auditory disturbances<br /> * Tactile disturbances<br /> * Paranoia/delusions<br /> * Orientation and clouding of sensorium<br /> <br /> <br /> Each item is rated on a scale (usually 0–4 or 0–7), and total scores are used to categorize severity:<br /> <br /> Mild: &lt; 20<br /> <br /> Moderate: 20–40<br /> <br /> Severe: &gt; 40<br /> <br /> == Clinical Use ==<br /> <br /> Best applied in inpatient or closely monitored outpatient settings.<br /> <br /> Can be used with symptom-triggered therapy: benzodiazepines are administered based on threshold scores rather than a fixed schedule.<br /> <br /> Assists in tailoring tapering protocols, especially when transitioning patients from high-dose or short-acting benzodiazepines.<br /> <br /> == Limitations ==<br /> <br /> Not as commonly used or validated as CIWA-Ar.<br /> <br /> May be more complex to administer due to the cognitive and perceptual domains assessed.<br /> <br /> Requires clinical judgment and experience to distinguish withdrawal symptoms from psychiatric comorbidity.<br /> <br /> == References ==<br /> <br /> Loebstein R, Shirazi I, Gomolin IH, et al. Clinical Institute Withdrawal Assessment–Benzodiazepines (CIWA-B): a tool for measuring benzodiazepine withdrawal. J Clin Psychopharmacol.<br /> <br /> American Psychiatric Association. Practice Guideline for the Treatment of Patients with Substance Use Disorders. 2nd ed. 2006.</div>

Cole Ettingoff